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Abstract Cardiac sodium channels have been shown to have a
higher sensitivity to local anesthetic agents, such as lidocaine,
than the sodium channels of other tissues. To examine if this is
also true for mexiletine, we have systematically measured
mexiletine sensitivity of the Na channel isoforms, rH1, W1, and
rBII, which were transiently expressed in human embryonic
kidney (HEK) 293 cells. We confirmed that the cardiac isoform
rH1 exhibited the highest sensitivity among the three tested
channel isoforms. In rH1, W1, and rBII, the respective IC50
values were 62, 294, and 308 WM mexiletine, in regard to tonic
block, and 18, 54, and 268 WM mexiletine, in relation to use
(8 Hz)-dependent block. The relatively high drug sensitivity of
rH1 was an invariant finding, irrespective of channel state or
whether channels were subjected to infrequent or frequent
depolarizing stimuli. Mutating specific amino acids in the
skeletal muscle isoform W1 (namely, W1-I433V and W1-S251A)
to those of the cardiac isoform at putative binding sites for local
anesthetic agents revealed that only one of the point mutations
(W1-S251A) has relevance to the high cardiac drug sensitivity,
because mexiletine produced significantly more use-dependent
and tonic block in W1-S251A than wild-type W1. ß 2002 Pub-
lished by Elsevier Science B.V. on behalf of the Federation of
European Biochemical Societies.
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1. Introduction
Mexiletine is an orally e¡ective lidocaine analog classi¢ed
as a class Ib antiarrhythmic agent. This drug is potentially
useful in various clinical settings, because it is e¡ective as an
antiarrhythmic [1], anticonvulsant [2], and local anesthetic
agent [3]. The use- and voltage-dependent blocking e¡ects of
mexiletine explain the suppressive action of mexiletine on neu-
ropathic pain [4] associated with post-traumatic neuromas,
post-amputation pain, and diabetic neuropathy [5]. Recently,
a neuroprotective e¡ect of mexiletine has been described [6] at
drug concentrations which have the potential also to produce
side e¡ects on organs that are not targeted, and must there-
fore be used with caution. The direct e¡ects of mexiletine on
various excitable tissues [7] depend on the membrane potential
and stimulation frequency [8^10]; thus the organ-speci¢c mex-
iletine a⁄nity could be largely due to di¡erences in action
potential duration and frequency. There may also be substan-
tial di¡erences in the intrinsic drug a⁄nity of the organ-spe-
ci¢c Na channel isoforms. However, a direct comparison has
yet to be made between the e¡ects of local anesthetics (LAs)
on di¡erent Na channel isoforms under uniform experimental
conditions. Thus, in the present study, our aim was to deter-
mine the mexiletine sensitivity of three Na channel isoforms,
rH1, rBII and W1, when expressed in human embryonic kid-
ney (HEK) 293 cells. By analysis of mutated channel isoforms,
we further undertook to explain the distinctly higher a⁄nity
of mexiletine in the cardiac isoform of the Na channel.
2. Materials and methods
2.1. Transient transfection and cell culture
The Na channels were constructed using three cDNA clones cod-
ing the K-subunits of rBII [11], rH1 [12] and W1 [13]. For introduction
of point mutations in domain 1 segment 6 (D1-S6) and domain 1
segment 4-segment 5 (D1S4-S5) intracellular loop, we used PCR-
based and site-directed mutagenesis (Promega Corp.). Resulting point
mutants were con¢rmed with restriction mapping and sequencing us-
ing an ABI PRISM1 310 Genetic Analyzer (Applied Biosystems).
Each cDNA clone was co-transfected with CD8 cDNA transiently
into HEK 293 using SuperFect transfection reagent (Qiagen). The
cells were grown to 50% con£uence in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) (Invitrogen) containing 10% fetal bovine serum
(Bio-whittaker), 30 units/ml penicillin G (Invitrogen) and 30 Wg/ml
streptomycin (Invitrogen) in a humidi¢ed atmosphere of 5% CO2
and 95% air at 37‡C. Transfection-positive cells were identi¢ed by
immunobeads (CD8-Dynabeads, Dynal) before the sodium current
recording.
2.2. Electrophysiological recording
Macroscopic sodium currents from the transfected cells were mea-
sured using the whole-cell variation of the patch clamp method. Elec-
trode resistances ranged from 1 to 2 M6. Voltage clamp command
pulses were generated by pCLAMP software (v. 7.0; Axon Instru-
ments, Inc.). An Axopatch 200B patch clamp ampli¢er was used
with series resistance compensation. The standard holding potential
in all pulse protocols was 3120 mV.
In every cell studied, we determined the blocking e¡ects of mexile-
tine, at a given concentration, and under infrequent and frequent
pulsing, according to the standard experimental protocol shown in
Fig. 1.
Data are presented as mean þ S.D. Experiments were carried out at
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a bath temperature of 19.0‡C rather than at room temperature, thus
allowing improved resolution of INa and greater viability of the cells
subjected to whole-cell patch clamp.
2.3. Drugs and solutions
The bath solution contained 70 mM NaCl, 67 mM N-methyl-D-
glucamine, 1 mM CaCl2, 1.5 mM MgCl2, 10 mM glucose, and
5 mM N-2-hydroxyethylpiperazine- NP-2-ethanesulfonic acid (HEPES)
(pH 7.4). The pipette solution contained 70 mM CsF, 60 mM CsCl,
12 mM NaF, 5 mM ethylene-bis(oxyethylenenitrilo)-tetraacetic acid
(EGTA), and 5 mM HEPES (pH 7.4). Mexiletine-hydrochloride was
obtained as a gift from Boehringer Ingelheim (Tokyo, Japan).
3. Results
3.1. Voltage-dependent activation and inactivation of
wild-type rBII, rH1 and W1 Na channels
Fig. 2 displays sodium currents through rBII (a), rH1 (b)
and W1 (c) channels expressed in HEK 293 cells, and their
current^voltage relationships. Currents through all three Na
channel isoforms had reversal potentials of approximately
+45 mV, which is in agreement with the theoretical value
for ENa (i.e. the reversal potential for Na) calculated from
the Na concentration of the internal and external solutions
used (see Section 2). Compared to both rBII and W1 isoforms,
rH1 Na channels were activated at less depolarized voltages
and had a more negative half-activation voltage (Fig. 2d).
Na currents through rH1 channels had longer inactivation
time constants than rBII and W1 (see the ¢gure legend for the
numerical data). Steady-state inactivation curves were ob-
tained with a standard double-pulse protocol using a 500-ms
prepulse duration. The rH1 sodium channel isoform was in-
activated at more negative transmembrane potentials than the
other two isoforms. The half-inactivation potentials (V0:5i)
and slope factors (k) were 394.0 þ 0.2 mV and 36.7 þ 0.2
for rH1 (n = 7), 372.1 þ 0.1 mV and 35.4 þ 0.1 for rBII
(n = 7), and 382.5 þ 0.1 mV and 36.0 þ 0.1 for W1 (n = 7),
respectively.
3.2. Use-dependent block
Use-dependent block is a key feature of LAs such as lido-
caine and mexiletine, i.e. their blocking e¡ect is enhanced as
the frequency of depolarizing pulses is increased. We com-
pared the three Na channel isoforms with respect to the use-
dependent block produced by application of mexiletine at
depolarization frequencies of 1, 2, 4, or 8 Hz. Fig. 3 depicts
the use-dependent block caused by mexiletine at a frequency
of 8 Hz. Mexiletine blocked all three sodium channel isoforms
in a concentration-dependent manner. The concentration de-
pendence of the block, at each of the stimulus frequen-
cies employed, has been summarized in Fig. 4 for all three
isoforms. IC50 values, obtained by ¢tting the equation
1/(1+([mexiletine]/IC50)) to these data, are listed in Table 1.
At any given pulsing frequency, the order of drug sensitivity
for the three isoforms was (from highest to lowest)
rH1sW1s rBII.
3.3. Tonic block
Use-dependent block of LAs has been explained by the
modulated receptor hypothesis [9,10,14], according to which
Fig. 1. Experimental protocols used throughout this study. The pulse protocols used are shown in a and b. a: Current^voltage (I^V) relation-
ship for INa was obtained by delivering, at 1 Hz, 20-ms depolarizing pulses to membrane potentials between 380 mV and +70 mV, from a
holding potential of 3120 mV. In the repetitive pulsing mode, we stimulated cells at 1, 2, 4, or 8 Hz with a depolarizing pulse train of 5 s to
one of three ¢xed potentials (340, 320 and 0 mV). b: The voltage dependence of steady-state Na inactivation was assessed by the double-pulse
protocol. 500-ms conditioning prepulses of various amplitudes were applied from a potential of 3140 mV followed by a 20-ms test pulse to
320 mV. Pulse pairs were applied every 5 s; holding potential was 3120 mV. c: Diagram showing the overall experimental procedure. The I^
V and double-pulse protocols were given sequentially where indicated (downward arrows). Trains of repetitive pulses to di¡erent test potentials
(a =340 mV, b =320 mV, and c = 0 mV) were given, as shown (upward arrows). Drugs were administered between 17 and 35 min from start
of experiments. The ¢rst I^V protocol was carried out 5 min after the beginning of drug perfusion.
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Fig. 2. Voltage-dependent properties of the three Na channel isoforms, rBII, rH1, and W1. The I^V relationships for currents through rBII,
rH1, and W1 channels are shown in a, b, and c, respectively. Data are expressed as mean (F) þ S.D. (error bars). Current records for each Na
channel isoform are shown in the insets. The inactivation phase of the currents are composed of two time constants, namely dfast and dslow (at
320 mV, dfast = 0.63 þ 0.086 ms and dslow = 2.4 þ 1.1 ms for rBII, n = 16; dfast = 0.81 þ 0.18 ms and dslow = 3.4 þ 0.83 ms for rH1, n = 12;
dfast = 0.58 þ 0.070 ms and dslow = 2.2 þ 0.93 ms for W1, n = 15). d: Normalized activation curves are shown for each isoform. The data points
(mean þ S.D.) have been ¢tted with a Boltzmann function (1/[1+exp((V0:5a3V)/k)]), where V0:5a is the half-activation voltage, and k is the slope
factor. V0:5a and k were 335.6 mV and 8.0, 336.0 mV and 8.4, and 355.6 mV and 6.8 for rBII (n = 7), W1 (n = 7), and rH1 (n = 7), respectively.
e: Steady-state inactivation (hr) curves for rBII, rH1, and W1 obtained by the double-pulse protocol. Normalized peak Na currents during the
test pulse are plotted against the potential of the conditioning prepulse. The data points (mean þ S.D.) have been ¢tted with a Boltzmann func-
tion (1/[1+exp((V3V0:5i)/k)]), where V0:5i is the half-inactivation voltage, and k the slope factor. V0:5i and k were 372.7 mV and 6.0, 383.3 mV
and 5.6, and 399.7 mV and 7.1 for rBII (n = 7), W1 (n = 7), and rH1 (n = 7), respectively.
Fig. 3. Time course of use-dependent block caused by mexiletine in the three Na channel isoforms, rBII, rH1 and W1. Cells were depolarized to
320 mV with a 5-s train of frequent (8 Hz) pulses in the absence or presence of mexiletine at the indicated concentrations. Data were ex-
pressed as mean þ S.D. and plotted against time for rBII (a), rH1 (b), and W1 (c) isoforms of Na channel K-subunits. Mexiletine concentration-
dependent block was observed in all the isoforms. Similar data were obtained with 340 and 0 mV test pulses, showing that block was not volt-
age dependent (data not shown).
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LAs possess a higher a⁄nity for open and inactivated chan-
nels than for resting channels. However, mexiletine was capa-
ble of suppressing INa without conditioning prepulses, indicat-
ing that resting block could be occurring. For this reason, we
measured the blocking e¡ect of mexiletine (tonic block) on INa
under conditions in which fast Na inactivation was fully re-
moved by holding the membrane at 3140 mV for 500 ms
(according to the double-pulse protocol used to study
steady-state inactivation of INa). As shown in Fig. 5a, mex-
iletine suppressed INa, elicited following a large hyperpolariz-
ing prepulse, in a dose-dependent manner. This e¡ect was
compared among the three Na channel isoforms (Fig. 5b).
IC50 values for tonic block are summarized in Table 1. Again,
rH1 was the most sensitive of the three isoforms to tonic
block induced by mexiletine. The two remaining isoforms
(rBII and W1) exhibited equivalent sensitivity to the tonic
block that mexiletine caused.
3.4. An amino acid residue of rH1 potentially conferring
high sensitivity to mexiletine block
Lipid-soluble toxin binding sites have been considered to be
potential binding sites for LAs that could in£uence Na chan-
nel sensitivity to LAs [15,16]. There are ¢ve known binding
sites for lipid-soluble toxins in domain 1 segment 6 (D1-S6)
and D4-S6 of the Na channel K-subunit (W1-N434, W1-L437,
W1-I1575, W1-F1579 and W1-Y1586) [15^18]. The indicated
amino acids are all homologous to those at corresponding
rH1 sites. In addition to these sites, we have recently found
grayanotoxin (GTX)-speci¢c binding sites in D1-S6 and the
S4^5 linker of D1 [19] that contain heterologous amino acid
residues in the rH1 and W1 isoforms (rH1-V406/W1-I433 and
rH1-A252/W1-S251). Among the seven known lipid-soluble
toxin binding sites, these are the only two toxin sites in rH1
and W1 that might be responsible for the higher sensitivity of
rH1 to the blocking e¡ects of mexiletine. Thus, we made four
Table 1
IC50 values for use-dependent and tonic block produced by mexiletine
n Use-dependent block Tonic block
1 Hz 2 Hz 4 Hz 8 Hz
rBII 3 2576 1068 522 268 308
rH1 3 192 93 40 18 62
W1 3 390 186 96 54 294
W1-I433V 3 585 214 92 44 278
W1-S251A 3 391 159 76 41 174
IC50 values are expressed in WM
Fig. 4. Concentration dependency of use-dependent block caused by mexiletine. After treatment with mexiletine, use-dependent block of INa
through all the three Na channel isoforms (rBII, rH1 and W1) was elicited by pulsing at four di¡erent stimulation frequencies (i.e. 1, 2, 4, or
8 Hz, as shown in a, b, c, and d, respectively). Lines through the data points were drawn according to the expression, 1/(1+([mexiletine]/IC50)),
where [mexiletine] indicates concentration of mexiletine, and IC50, the concentration at which INa was decreased to half of its basal value (in
the absence of mexiletine). We estimated IC50 values for mexiletine at each pulse frequency used. Values of IC50 are summarized in Table 1.
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mutant Na channels, including rH1-V406I, W1-I433V, rH1-
A252S and W1-S251A, and examined e¡ects of mexiletine on
these mutants. We could not obtain an IC50 value with respect
to tonic block from two of the mutants (rH1-A252S and rH1-
V406I), because a large hyperpolarizing shift of the steady-
state inactivation curve hampered evaluation of the tonic
blocking e¡ect of mexiletine. (As Na inactivation could not
be fully removed, drug-bound inactivated channels might tend
to accumulate during the course of an experiment, thus ob-
scuring the tonic blocking e¡ect of mexiletine.) Unexpectedly,
Fig. 5. Concentration dependency of tonic block among the Na channel isoforms. Tonic block of INa induced by mexiletine was measured
under maximal relief of inactivation. a: Test INa was elicited, following the pulse protocol for steady-state inactivation, and measured at di¡er-
ent concentrations of mexiletine. b: Test INa, elicited following a hyperpolarizing prepulse to 3140 mV, was used as the index of tonic block.
Lines through symbols were drawn as in Fig. 4. IC50 values for tonic block are listed in Table 1.
Fig. 6. Concentration dependency of tonic and use-dependent block produced by mexiletine in WT-W1 and its mutants. Lines drawn through
symbols are ¢tted as in Fig. 4. a,b: Use-dependent (a) and tonic (b) blocking e¡ect of mexiletine in WT-W1, W1-I433V and W1-S251A. Signi¢-
cant increase in sensitivity to mexiletine compared with WT-W1 is indicated by *, and signi¢cant decrease in sensitivity compared with WT-W1
is indicated by ** (P6 0.05).
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there was no clear di¡erence in sensitivity to mexiletine be-
tween WT- (wild-type) W1 and W1-I433V, and W1-I433V even
showed reduced sensitivity at some concentrations of mexile-
tine (v indicated with ** in Fig. 6). By contrast, W1-S251A
exhibited higher sensitivity to mexiletine (v indicated with * in
Fig. 6) than WT-W1 with respect to both use-dependent block
at 2, 4, and 8 Hz and tonic block (Fig. 6 and Table 1). These
results thus revealed a novel site in the S4^5 linker of D1 (W1-
S251) of the Na channel that alters the channel’s a⁄nity to
mexiletine.
3.5. Mexiletine-induced shift of voltage dependency of
activation and inactivation curves
It has been reported that LAs a¡ect the voltage dependency
of activation and inactivation in addition to their blocking
e¡ects [20,21]. However, in the present study, we noticed
that these curves were spontaneously shifted in the negative
direction (without drug application) during the course of
whole-cell voltage clamp experiments. Thus, we measured
the size of spontaneous negative shifts in separate control
experiments using our standard experimental protocol (see
Fig. 1), but without mexiletine application. Between the
13th and 30th min of these control experiments, V0:5i was
shifted in the negative direction by 7.4 þ 1.3 mV (n = 3) for
rBII, by 11.5 þ 2.3 mV (n = 3) for rH1, and by 7.4 þ 3.1 mV
(n = 3) for W1. The corrected half-inactivation voltages (V0:5i)
at 30, 100, or 300 WM mexiletine (applied between min 17 and
35), which we estimated by taking into account the values
obtained in the control experiments above, are tabulated in
Table 2. There was a tendency for mexiletine to cause a neg-
ative shift in V0:5i, which was reversible on drug washout in
rBII and W1. For rH1, there was no negative shift in V0:5i on
application of mexiletine. Perhaps the e¡ect of mexiletine
causing a negative shift in V0:5i was also present in rH1 experi-
ments, but a correction of large spontaneous shift of V0:5i in
rH1 could have obscured a shift produced by mexiletine.
4. Discussion
We have shown that rH1 was more sensitive to mexiletine
block than two other Na channel isoforms (rBII and W1)
under uniform experimental conditions in which the K-subunit
of the respective Na channels was transfected into HEK 293
cells. This demonstrates that the site responsible for the or-
gan-speci¢c di¡erences in sensitivity to mexiletine block re-
sides in the K-subunit of the Na channel. Although mutation
of W1-I433V did not reveal a clear-cut site responsible for the
higher sensitivity of the cardiac isoform, the W1-S251A mutant
exhibited a smaller IC50 than WT-W1 with respect to both use-
dependent block at 2, 4, and 8 Hz and tonic block. Thus, this
site, located in the S4^5 linker of D1, has an in£uence on the
sensitivity of the channel to mexiletine.
4.1. Physiological relevance of sensitivity di¡erences of
Na channel isoforms to mexiletine
The higher LA sensitivity of cardiac Na channels in com-
parison to channel isoforms in other organs has not been
systemically explored, although the clinical use of LAs as
antiarrhythmic agents without signi¢cant side e¡ects may sug-
gest that this is the case. Recently, comparisons of lidocaine
e¡ects between hH1 and hSkM1 [22], and R-mexiletine e¡ects
between rH1 and rBIIA [23] have been made. These reports
show a higher LA sensitivity of Na channel isoforms of car-
diac muscle than isoforms of other tissues. In this study, we
have now clearly shown the order of sensitivity to mexiletine
both in terms of use-dependent and tonic block, i.e.
rH1sW1s rBII. This is important; because the higher sensi-
tivity of the heart compared to other tissues emphasizes that
any clinical application of mexiletine to skeletal muscle or the
central nervous system requires careful monitoring of cardiac
rhythms.
4.2. Possible sites responsible for sensitivity di¡erences among
the Na channel isoforms
It has not been clearly shown what sites within the K-sub-
unit are responsible for the higher LA sensitivity of the car-
diac isoform of Na channels. Thus, it is important to compare
the e¡ects of mexiletine on Na channel K-subunit isoforms
without co-transfection with L-subunit, although recent report
indicates that the presence of the L-subunit may a¡ect the
a⁄nity on LAs to sodium channels [24].
Weiser et al. indicated that mutation of the homologous
phenylalanine residue of rBIIF1764/rH1F1762 to alanine re-
duced block to a similar extent but with di¡erent mechanisms,
one by slowing the rate of drug binding (rBIIF1764A) and the
other by increasing the rate of drug dissociation
(rH1F1762A). These investigators also showed that mutation
of Y1771A in rBII exhibited the strongest reduction of block
by R-mexiletine. These sites in D4-S6 coincide with the recep-
tor sites for lipid-soluble toxins, such as batrachotoxin (BTX)
Table 2
Half-inactivation voltages under mexiletine
N V0:5C V0:5D vV0:5DÿC V0:5W vV0:5WÿD
rBII (30 WM) 3 374.7 þ 0.5 376.9 þ 1.4 32.2 þ 0.9 376.1 þ 1.6 0.8 þ 0.9
(0.1 mM) 3 367.7 þ 5.3 377.4 þ 0.6 39.7 þ 5.3 374.7 þ 2.8 2.7 þ 3.3
(0.3 mM) 3 375.1 þ 4.6 381.8 þ 6.1* 36.7 þ 1.7 374.8 þ 5.1 7.0 þ 1.1
rH1 (10 WM) 3 390.1 þ 4.1 389.7 þ 3.7 0.4 þ 0.5 388.3 þ 5.0 1.4 þ 1.3
(30 WM) 3 391.0 þ 0.2 389.2 þ 2.2 1.7 þ 2.3 385.3 þ 1.2 3.9 þ 1.2
(0.1 mM) 3 394.9 þ 7.0 396.0 þ 1.9 31.1 þ 5.1 389.7 þ 1.9 6.3 þ 3.0
W1 (10 WM) 3 383.9 þ 1.1 385.4 þ 4.1 31.5 þ 4.7 384.8 þ 6.2 0.6 þ 2.2
(30 WM) 3 380.2 þ 0.2 382.4 þ 1.1 32.2 þ 1.0 380.2 þ 0.6 2.2 þ 1.7
(0.1 mM) 3 378.4 þ 1.6 380.5 þ 3.1 32.2 þ 2.3 374.0 þ 4.1# 6.6 þ 1.2
Data are corrected for spontaneous voltage shifts that occurred in the absence of mexiletine (see text). V0:5C were measured at 11 min in the
absence of mexiletine, V0:5D, at 29 min during application of mexiletine. Washout of drug was begun after 23 min of mexiletine application,
and V0:5W was determined 5 min after the start of washout. Thus, vV0:5DÿC = V0:5D3V0:5C and vV0:5WÿD = V0:5W3V0:5D, indicating the
true shifts in V0:5 that occurred during the various treatments. Signi¢cant di¡erence (P6 0.05) from V0:5C or V0:5D is indicated by * or by #,
respectively.
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[16] or grayanotoxin (GTX) [18]. Thus, investigating other
lipid-soluble toxin binding sites may lead to the discovery of
sites required for the high cardiac sensitivity of mexiletine.
Indeed, we recently reported that mutation of W1-I433 and
W1-S251 to the corresponding amino acid residues of rH1-
V406 and rH1-A252 reduced the sensitivity to GTX [19].
Therefore, we presumed that mutation of W1-I433V and W1-
S251A should enhance, and that of rH1-V406I and rH1-
A252S should reduce mexiletine sensitivity. However, our ex-
perimental results di¡ered from expectation. Unfortunately,
we could not obtain useful data from the mutants of rH1
due to a severe hyperpolarizing shift of the steady-state inac-
tivation curve. Unexpectedly, W1-I433V did not show a sig-
ni¢cant di¡erence in sensitivity from that of WT-W1. W1-
S251A did increase the sensitivity. Thus, we could at least
point out one possible site responsible for the high cardiac
sensitivity to mexiletine. At the same time, we should give
some explanation for the increased sensitivity of W1-S251A.
Does this mutation cause a direct modulation of mexiletine
binding a⁄nity? We cannot give a clear answer to this ques-
tion, because this mutant exhibited changes in inactivation
properties. V0:5i of W1-S251A (386.3 þ 0.8 mV, n = 9) was sig-
ni¢cantly shifted in the hyperpolarizing direction compared
with that of wild-type W1 (381.4 þ 0.7 mV, n = 12), and the
fast time constant for current decay (dfast = 0.52 þ 0.02 ms,
n = 9) of W1-S251A was signi¢cantly briefer than that of W1
(0.58 þ 0.07 ms, n = 15). However, dslow was not signi¢cantly
di¡erent (2.2 þ 0.2 ms, n = 15 for W1 vs. 2.5 þ 0.7 ms, n = 9 for
W1-S251A). The change in inactivation properties may well
imply increased numbers of inactivated Na channels under
the same experimental conditions, leading to a higher sensi-
tivity of these mutants to mexiletine block, because LAs are
thought to bind more tightly to the inactivated channel state
[9].
4.3. Voltage shift of steady-state inactivation curve
Depolarization-enhanced e¡ects of LAs were explained by
the modulated receptor hypothesis [9] according to which
drug binds more tightly to inactivated states of the channel
than to the resting state. If that is so, and given that mexile-
tine is a known blocker of inactivated channels [25^27], the
steady-state inactivation curve in the presence of mexiletine
should shift to more negative membrane potentials. In fact,
very small negative shifts (V5 mV) of the steady-state inacti-
vation curve of hSkm1 Na channels expressed in HEK 293
cells have been reported to occur in the presence of 100^500
WM mexiletine [28,29], and a large shift was observed only at a
very high dose (1 mM) [29]. The shift is more obvious (V20
mV) in Na channels expressed in Xenopus oocytes, where a
spontaneous negative was not observed [30]. In our study,
mexiletine-speci¢c negative shifts were variable among the
Na channel isoforms (2^9 mV): rBII exhibited most marked
shift, while rH1 did not show any signi¢cant shift after cor-
rection for spontaneous shifts. The shift could be masked by
two properties of our experimental system utilized in this
study: an intrinsically small negative shift due to LAs in
mammalian expression systems, and a large spontaneous shift
in rH1.
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